Skip to
  1. Homepage
  2. Rare diseases
  3. Search
Simple search

Simple search

*
(*) mandatory field





 

Other search option(s)

Multiple endocrine neoplasia type 1

Orpha number ORPHA652
Synonym(s) MEN 1
Wermer syndrome
Prevalence 1-9 / 100 000
Inheritance Not applicable
Autosomal dominant
Age of onset All ages
ICD-10
  • D44.8
ICD-O -
OMIM
UMLS
  • C0025267
MeSH
  • D018761
MedDRA
  • 10028190

Summary

Multiple Endocrine Neoplasia type 1 (MEN1) is a rare hereditary cancer syndrome marked mainly by tumours of the parathyroids, endocrine pancreas and anterior pituitary, and characterised by a very high penetrance and an equal sex distribution. It occurs in approximately one in 30,000 individuals. Two different forms, sporadic and familial, have been described. The sporadic form presents with two of the three principal MEN1-related endocrine tumours (parathyroid adenomas, entero-pancreatic tumours and pituitary tumours) within a single patient, while the familial form consists of a MEN1 case with at least one first-degree relative showing one of the characteristic endocrine tumours. Other endocrine and non-endocrine lesions, such as adrenal cortical tumours, carcinoids of the bronchi, gastrointestinal tract and thymus, lipomas, angiofibromas, and collagenomas have been described. The syndrome is transmitted as an autosomal dominant trait. MEN1 syndrome is caused by inactivating mutations of the MEN1 tumour suppressor gene. MEN1 maps to chromosome 11q13 and encodes a 610 aminoacid nuclear protein, menin, which shows no sequence homology to other known human proteins. This gene is probably involved in the regulation of several cell functions such as DNA replication and repair, and transcriptional machinery. The combination of clinical and genetic investigations, together with the improving knowledge of the molecular genetics of the syndrome, has led to progress in the clinical management of patients. Treatment consists of surgery and/or drug therapy, often in association with radiotherapy or chemotherapy. DNA testing allows the early identification of germline mutations in asymptomatic gene carriers, for whom routine surveillance (regular biochemical and/or radiological screening to detect the development of MEN1-associated tumours and lesions) is recommended.

Expert reviewer(s)

  • Pr Maria Luisa BRANDI
  • Dr Francesca DEL MONTE
  • Dr Alberto FALCHETTI
  • Dr Alessia GOZZINI
  • Dr Ettore LUZI
  • Dr Francesca MARINI
  • Dr S.C SALA

(*) Required fields.

Attention: Only comments seeking to improve the quality and accuracy of information on the Orphanet website are accepted. For all other comments, please send your remarks via contact us. Only comments written in English can be processed.


Captcha image

Detailed information

Summary information
Review article
  • EN (2006)
Clinical genetics review
  • EN (2012)
Get Acrobat Reader
The documents contained in this web site are presented for information purposes only. The material is in no way intended to replace professional medical care by a qualified specialist and should not be used as a basis for diagnosis or treatment.